Literature DB >> 19608668

Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.

Emmanuelle Boulanger1, Agnès Marchio, Saw-See Hong, Pascal Pineau.   

Abstract

Human herpesvirus 8 (HHV-8)-associated primary effusion lymphoma is a rare non-Hodgkin's lymphoma often associated with Epstein-Barr virus (EBV) infection. Mutations in TP53, PTEN, PIK3CA, CTNNB1/beta-catenin genes and deletion of CDKN2A-ARF (p14(ARF)-p16(NK4a I) ) locus were investigated in sixteen primary primary effusion lymphoma tumors and seven primary effusion lymphoma cell lines using PCR and sequencing. TP53 mutations were detected in one primary primary effusion lymphoma tumor (6.2%) and two primary effusion lymphoma cell lines (28.6%). BC-3 and BCP-1 cell lines showed PTEN gene mutations, associated with a loss of PTEN protein expression in both cases. No mutations were detected in PIK3CA and CTNNB1/beta-catenin hotspot sequences. Only BC-3 contained a homozygous deletion of CDKN2A-ARF locus. Although detected at a higher frequency in primary effusion lymphoma cell lines than in primary primary effusion lymphoma tumors, TP53 and/or PTEN mutations, as well as deletion of CDKN2A-ARF locus are uncommon in primary effusion lymphoma, and are found to correlate with the EBV-negative status of primary effusion lymphoma tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608668      PMCID: PMC2719041          DOI: 10.3324/haematol.2009.007260

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis.

Authors:  T Seo; J Park; D Lee; S G Hwang; J Choe
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus.

Authors:  E M Maggio; E Stekelenburg; A Van den Berg; S Poppema
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

3.  PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.

Authors:  J Abubaker; P P Bavi; S Al-Harbi; A K Siraj; F Al-Dayel; S Uddin; K Al-Kuraya
Journal:  Leukemia       Date:  2007-07-26       Impact factor: 11.528

4.  TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.

Authors:  Norafiza Zainuddin; Mattias Berglund; Alkwin Wanders; Zhi-Ping Ren; Rose-Marie Amini; Monica Lindell; Meena Kanduri; Göran Roos; Richard Rosenquist; Gunilla Enblad
Journal:  Leuk Res       Date:  2008-08-15       Impact factor: 3.156

5.  Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies.

Authors:  H Katano; Y Sato; T Sata
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

6.  Mutations of the PIK3CA gene in diffuse large B cell lymphoma.

Authors:  Yu Baohua; Zhou Xiaoyan; Zhang Tiecheng; Qin Tao; Shi Daren
Journal:  Diagn Mol Pathol       Date:  2008-09

7.  Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients.

Authors:  Yoshihiko Hoshida; Tadashi Hongyo; Shin-ichi Nakatsuka; Mieko Nishiu; Tetsuya Takakuwa; Yasuhiko Tomita; Taisei Nomura; Katsuyuki Aozasa
Journal:  Lab Invest       Date:  2002-03       Impact factor: 5.662

8.  p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma.

Authors:  Georgina Platt; Antonino Carbone; Sibylle Mittnacht
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

9.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Authors:  Patrick Dumont; J I-Ju Leu; Anthony C Della Pietra; Donna L George; Maureen Murphy
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

10.  Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.

Authors:  E Boulanger; P V Afonso; Y Yahiaoui; H Adle-Biassette; J Gabarre; F Agbalika
Journal:  Am J Transplant       Date:  2008-02-05       Impact factor: 8.086

View more
  12 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  Debasmita Roy; Dirk P Dittmer
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

3.  Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

Authors:  Aadra P Bhatt; Prasanna M Bhende; Sang-Hoon Sin; Debasmita Roy; Dirk P Dittmer; Blossom Damania
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

4.  Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Authors:  Debasmita Roy; Sang-Hoon Sin; Blossom Damania; Dirk P Dittmer
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

5.  p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3.

Authors:  Petra Baresova; Jana Musilova; Paula M Pitha; Barbora Lubyova
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

Review 6.  Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies.

Authors:  Eleonora Ruocco; Vincenzo Ruocco; Maria Lina Tornesello; Alessio Gambardella; Ronni Wolf; Franco M Buonaguro
Journal:  Clin Dermatol       Date:  2013 Jul-Aug       Impact factor: 3.541

7.  Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas.

Authors:  Ricardo Rivera-Soto; Yi Yu; Dirk P Dittmer; Blossom Damania
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

8.  The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.

Authors:  Samantha D Pauls; Sandrine T Lafarge; Ivan Landego; Tingting Zhang; Aaron J Marshall
Journal:  Front Immunol       Date:  2012-08-09       Impact factor: 7.561

9.  HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma.

Authors:  M Granato; V Lacconi; M Peddis; L V Lotti; L Di Renzo; L D Renzo; R Gonnella; R Santarelli; P Trivedi; L Frati; G D'Orazi; A Faggioni; M Cirone
Journal:  Cell Death Dis       Date:  2013-07-18       Impact factor: 8.469

10.  RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.

Authors:  Gail Anderson; Nancy Mackay; Kathryn Gilroy; Jodie Hay; Gillian Borland; Alma McDonald; Margaret Bell; Siti Ayuni Hassanudin; Ewan Cameron; James C Neil; Anna Kilbey
Journal:  J Cell Biochem       Date:  2017-11-20       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.